Novartis assembles 2nd molecular glue deal with Monte Rosa, this one worth up to $5.7B Fierce Biotech Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases GlobeNewswire Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics Yahoo Finance Updated: Novartis extends deal spree with $120M for Monte Rosa’s immune degraders Endpoints News Novartis dives deeper into protein …
Read More »Tag Archives: 5.7B
Monte Rosa’s Stock (GLUE) Skyrockets on $5.7B Deal with Novartis
Swiss giant drug producer Novartis (NVS) has found a new destination for its recent partnership spree. On Monday, Monte Rosa Therapeutics (GLUE), a Massachusetts-based biotech company, disclosed its second deal with Novartis, with Monte’s shares exploding over 50% in early trading to more than $7. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing …
Read More »